
Isidoro MartÃ-nez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7157227/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. Journal of Virology, 1994, 68, 5448-5459.	3.4	190
2	Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein Journal of General Virology, 1997, 78, 2411-2418.	2.9	188
3	Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants Journal of General Virology, 1997, 78, 2419-2429.	2.9	130
4	Vitamin D in Human Immunodeficiency Virus Infection: Influence on Immunity and Disease. Frontiers in Immunology, 2018, 9, 458.	4.8	110
5	TRIM25 in the Regulation of the Antiviral Innate Immunity. Frontiers in Immunology, 2017, 8, 1187.	4.8	109
6	Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. Journal of General Virology, 2000, 81, 2715-2722.	2.9	91
7	Host Cell Effect upon Glycosylation and Antigenicity of Human Respiratory Syncytial Virus G Glycoprotein. Virology, 1996, 221, 301-309.	2.4	66
8	Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. Journal of General Virology, 2007, 88, 570-581.	2.9	63
9	Respiratory Syncytial Virus Inhibits Ciliagenesis in Differentiated Normal Human Bronchial Epithelial Cells: Effectiveness of N-Acetylcysteine. PLoS ONE, 2012, 7, e48037.	2.5	62
10	Evolutionary pattern of the G glycoprotein of human respiratory syncytial viruses from antigenic group B: the use of alternative termination codons and lineage diversification Journal of General Virology, 1999, 80, 125-130.	2.9	61
11	ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation. Journal of Virology, 2016, 90, 3428-3438.	3.4	56
12	Vesicular Stomatitis Virus Glycoprotein Is a Determinant of Pathogenesis in Swine, a Natural Host. Journal of Virology, 2003, 77, 8039-8047.	3.4	50
13	Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus. Virulence, 2016, 7, 427-442.	4.4	49
14	Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein Journal of General Virology, 1998, 79, 2215-2220.	2.9	40
15	A model for the generation of multiple A to G transitions in the human respiratory syncytial virus genome: predicted RNA secondary structures as substrates for adenosine deaminases that act on RNA. Journal of General Virology, 2002, 83, 1445-1455.	2.9	37
16	Metabolic changes during respiratory syncytial virus infection of epithelial cells. PLoS ONE, 2020, 15, e0230844.	2.5	35
17	Roflumilast Inhibits Respiratory Syncytial Virus Infection in Human Differentiated Bronchial Epithelial Cells. PLoS ONE, 2013, 8, e69670.	2.5	32
18	Cultures of HEp-2 cells persistently infected by human respiratory syncytial virus differ in chemokine expression and resistance to apoptosis as compared to lytic infections of the same cell type. Virology, 2009, 388, 31-41.	2.4	26

Isidoro MartÃnez

#	Article	IF	CITATIONS
19	Hepatitis C virus vaccine design: focus on the humoral immune response. Journal of Biomedical Science, 2020, 27, 78.	7.0	23
20	Apoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens. Frontiers in Microbiology, 2017, 8, 276.	3.5	22
21	Low antiâ€SARSâ€CoVâ€2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVIDâ€19 patients. Journal of Internal Medicine, 2022, 291, 232-240.	6.0	21
22	Biological Differences between Vesicular Stomatitis Virus Indiana and New Jersey Serotype Glycoproteins: Identification of Amino Acid Residues Modulating pH-Dependent Infectivity. Journal of Virology, 2005, 79, 3578-3585.	3.4	20
23	Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients. Journal of Translational Medicine, 2016, 14, 257.	4.4	20
24	Unusual Antigenic and Genetic Characteristics of Human Respiratory Syncytial Viruses Isolated in Cuba. Journal of Virology, 1998, 72, 7589-7592.	3.4	16
25	Mapping of Monoclonal Antibody Epitopes of the Human Respiratory Syncytial Virus P Protein. Virology, 1993, 195, 239-242.	2.4	14
26	HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Frontiers in Immunology, 2021, 12, 723196.	4.8	14
27	Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host. Vaccine, 2004, 22, 4035-4043.	3.8	12
28	Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines, 2020, 8, 313.	4.4	12
29	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs, 2021, 81, 419-443.	10.9	12
30	Downregulation of A20 Expression Increases the Immune Response and Apoptosis and Reduces Virus Production in Cells Infected by the Human Respiratory Syncytial Virus. Vaccines, 2020, 8, 100.	4.4	11
31	Chimeric <i>Pneumoviridae</i> fusion proteins as immunogens to induce crossâ€neutralizing antibody responses. EMBO Molecular Medicine, 2018, 10, 175-187.	6.9	10
32	Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. International Journal of Drug Policy, 2021, 96, 103424.	3.3	10
33	A Two-Dimensional Human Minilung System (Model) for Respiratory Syncytial Virus Infections. Viruses, 2017, 9, 379.	3.3	8
34	Reduced innate immune response, apoptosis, and virus release in cells cured of respiratory syncytial virus persistent infection. Virology, 2011, 410, 56-63.	2.4	7
35	Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. Biomolecules, 2019, 9, 143.	4.0	7
36	Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. Journal of Infection, 2022, 84, 418-467.	3.3	7

Isidoro MartÃnez

#	ARTICLE	IF	CITATIONS
37	Reduced expression of surface glycoproteins in mouse fibroblasts persistently infected with human respiratory syncytial virus (HRSV). Archives of Virology, 2001, 146, 669-683.	2.1	6
38	HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. Journal of Biomedical Science, 2021, 28, 23.	7.0	6
39	Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomedicine and Pharmacotherapy, 2022, 147, 112623.	5.6	6
40	Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination/deubiquitination processes. Journal of Biomedical Science, 2022, 29, 11.	7.0	6
41	Urokinase receptor-deficient mice mount an innate immune response to and clarify respiratory viruses as efficiently as wild-type mice. Virulence, 2015, 6, 710-715.	4.4	5
42	siRNA-Mediated Simultaneous Regulation of the Cellular Innate Immune Response and Human Respiratory Syncytial Virus Replication. Biomolecules, 2019, 9, 165.	4.0	5
43	TNFAIP3, TNIP1, and MyD88 Polymorphisms Predict Septic-Shock-Related Death in Patients Who Underwent Major Surgery. Journal of Clinical Medicine, 2019, 8, 283.	2.4	5
44	The Challenging Road to Hepatitis C Virus Eradication. Journal of Clinical Medicine, 2021, 10, 611.	2.4	5
45	Antibody levels to <scp>SARSâ€CoV</scp> â€2 spike protein in mothers and children from delivery to six months later. Birth, 2023, 50, 418-427.	2.2	5
46	Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case–control study. Aids, 2020, 34, 1891-1897.	2.2	4
47	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR. Scientific Reports, 2019, 9, 12163.	3.3	2
48	Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study. Infection, Genetics and Evolution, 2019, 67, 112-120.	2.3	2
49	Role of G2-S16 Polyanionic Carbosilane Dendrimer in the Prevention of Respiratory Syncytial Virus Infection In Vitro and In Vivo in Mice. Polymers, 2021, 13, 2141.	4.5	2
50	Hepatitis E Virus Seroprevalence is Associated with Neurodegenerative Disorders in Older People with Dementia: A Case-Control Study. Journal of Infectious Diseases, 0, , .	4.0	2
51	TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. Journal of Clinical Medicine, 2021, 10, 483.	2.4	1
52	Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis. Biomedicine and Pharmacotherapy, 2022, 150, 113024.	5.6	1
53	Misdiagnosis rate among negative COVID-19 patients in real-life with Panbio COVID-19 antigen rapid test during 2021. Journal of Infection, 2022, , .	3.3	0